Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | El-Naggar A.M. | |
dc.contributor.author | Abou-El-Regal M.M. | |
dc.contributor.author | El-Metwally S.A. | |
dc.contributor.author | Sherbiny F.F. | |
dc.contributor.author | Eissa I.H. | |
dc.contributor.other | Chemistry Department | |
dc.contributor.other | Faculty of Science | |
dc.contributor.other | Ain Shams University | |
dc.contributor.other | Abbassia | |
dc.contributor.other | Cairo | |
dc.contributor.other | 11566 | |
dc.contributor.other | Egypt; Higher Technology Institute | |
dc.contributor.other | 10th of Ramadan City | |
dc.contributor.other | Egypt; Organic Chemistry Department | |
dc.contributor.other | Faculty of Pharmacy (Boys) | |
dc.contributor.other | Al-Azhar University | |
dc.contributor.other | Cairo | |
dc.contributor.other | 11884 | |
dc.contributor.other | Egypt; Organic Chemistry Department | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | October University for Modern Science and Arts (MSA) | |
dc.contributor.other | 6th October City | |
dc.contributor.other | 11787 | |
dc.contributor.other | Egypt; Pharmaceutical Chemistry Department | |
dc.contributor.other | Faculty of Pharmacy (Boys) | |
dc.contributor.other | Al-Azhar University | |
dc.contributor.other | Cairo | |
dc.contributor.other | 11884 | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:14Z | |
dc.date.available | 2020-01-09T20:41:14Z | |
dc.date.issued | 2017 | |
dc.description | Scopus | |
dc.description.abstract | Thymidylate synthase (TS), one of folate-dependent enzymes, is a key and well-recognized target for anticancer agents. In this study, a series of 6-aryl-5-cyano thiouracil derivatives were designed and synthesized in accordance with essential pharmacophoric features of known TS inhibitors. Nineteen compounds were screened in vitro for their anti-proliferative activities toward HePG-2, MCF-7, HCT-116, and PC-3 cell lines. Compounds 21c, 21d, and 24 exhibited high anti-proliferative activity, comparable to that of 5-fluorouracil. Additionally, ten compounds with potent anti-proliferative activities were further evaluated for their ability to inhibit TS enzyme. Six compounds (21b, 21c, 21d, 22, 23 and 24) demonstrated potent dose-related TS inhibition with IC 50 values ranging from 1.57 to 3.89?M. The in vitro TS activity results were consistent with those of the cytotoxicity assay where the most potent anti-proliferative compounds of the series showed good TS inhibitory activity comparable to that of 5-fluorouracil. Furthermore, molecular docking studies were carried out to investigate the binding pattern of the designed compounds with the prospective target, TS (PDB-code: 1JU6). � 2017, Springer International Publishing AG. | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=29053&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.1007/s11030-017-9776-1 | |
dc.identifier.doi | PubMed ID 28815411 | |
dc.identifier.issn | 13811991 | |
dc.identifier.other | https://doi.org/10.1007/s11030-017-9776-1 | |
dc.identifier.other | PubMed ID 28815411 | |
dc.identifier.uri | https://t.ly/52wBX | |
dc.language.iso | English | en_US |
dc.publisher | Springer International Publishing | en_US |
dc.relation.ispartofseries | Molecular Diversity | |
dc.relation.ispartofseries | 21 | |
dc.subject | 6-Aryl-5-cyano thiouracil | en_US |
dc.subject | Anticancer | en_US |
dc.subject | Docking | en_US |
dc.subject | Thymidylate synthase | en_US |
dc.subject | 1 benzyl 2 (benzylthio) 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidine 5 carbonitrile | en_US |
dc.subject | 2 (allylthio) 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidine 5 carbonitrile | en_US |
dc.subject | 2 (allylthio) 6 oxo 4 phenyl 1,6 dihydropyrimidine 5 carbonitrile | en_US |
dc.subject | 2 (benzylthio) 6 oxo 1,4 diphenyl 1,6 dihydropyrimidine 5 carbonitrile | en_US |
dc.subject | 2 [[(naphthalen 2 ylamino)methyl]thio] 6 oxo 4 phenyl 1,6 dihydropyrimidine 5 carbonitrile | en_US |
dc.subject | 2 [[5 cyano 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidin 2 yl]thio]acetic acid | en_US |
dc.subject | 2,2' [methylenebis(sulfanediyl)]bis[4 (4 methoxyphenyl) 6 oxo 1,6 dihydro pyrimidine 5 carbonitrile] | en_US |
dc.subject | 2,5 dioxo 7 phenyl 2,3 dihydro 5h thiazolo[3,2 a]pyrimi dine 6 carbonitrile | en_US |
dc.subject | 3 (4 methoxyphenyl) 6 oxo 8 phenyl 3,4 dihydro 2h,6h pyrimido[2,1 b][1,3,5]thiadiazine 7 carbonitrile | en_US |
dc.subject | 3 isobutyl 6 oxo 8 phenyl 3,4 dihydro 2h,6h pyrimido [2,1 b][1,3,5]thiadiazine 7 carbonitrile | en_US |
dc.subject | 3,8 bis(4 methoxyphenyl) 6 oxo 3,4 dihydro 2h,6h pyrimido[2,1 b][1,3,5]thiadiaine 7 carbonitrile | en_US |
dc.subject | 6 oxo 8 phenyl 3 (4 tolyl) 3,4 dihydro 2h,6h pyrimido [2,1 b][1,3,5]thiadiazine 7 carbonitrile | en_US |
dc.subject | 6 oxo 8 phenyl 3 (pyrimidin 2 yl) 3,4 dihydro 2h,6h pyrimido[2,1 b][1,3, 5]thiadiazine 7 carbonitrile | en_US |
dc.subject | 7 (4 methoxyphenyl) 5 oxo 2,3 dihydro 5h thiazolo[3,2 a]pyrimidine 6 carbonitrile | en_US |
dc.subject | 8 (4 methoxyphenyl) 6 oxo 3 (4 tolyl) 3,4 dihydro 2h, 6h pyrimido[2,1 b][1,3,5]thiadiaine 7 carbonitrile | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | diethyl2 [[5 cyano 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidin 2 l]thio]vmalonate | en_US |
dc.subject | ethyl 2 [[5 cyano 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidin 2 yl]thio]acetate | en_US |
dc.subject | ethyl2 [(5 cyano 6 oxo 4 phenyl 1,6 dihydropyrimidin 2 yl)thio]acetate | en_US |
dc.subject | fluorouracil | en_US |
dc.subject | pemetrexed | en_US |
dc.subject | thiouracil derivative | en_US |
dc.subject | thymidylate synthase | en_US |
dc.subject | thymidylate synthase inhibitor | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | [5 cyano 4 (4 methoxyphenyl) 6 oxo 1,6 dihydropyrimidin 2 yl]propane thioate | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | enzyme inhibitor | en_US |
dc.subject | thiouracil | en_US |
dc.subject | thymidylate synthase | en_US |
dc.subject | antineoplastic activity | en_US |
dc.subject | antiproliferative activity | en_US |
dc.subject | Article | en_US |
dc.subject | BxPC-3 cell line | en_US |
dc.subject | controlled study | en_US |
dc.subject | cytotoxicity | en_US |
dc.subject | drug design | en_US |
dc.subject | drug determination | en_US |
dc.subject | drug screening | en_US |
dc.subject | drug structure | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | enzyme inhibition | en_US |
dc.subject | Hep-G2 cell line | en_US |
dc.subject | human | en_US |
dc.subject | human cell | en_US |
dc.subject | IC50 | en_US |
dc.subject | in vitro study | en_US |
dc.subject | MCF-7 cell line | en_US |
dc.subject | molecular docking | en_US |
dc.subject | p53HCT116 cell line | en_US |
dc.subject | priority journal | en_US |
dc.subject | antagonists and inhibitors | en_US |
dc.subject | chemistry | en_US |
dc.subject | metabolism | en_US |
dc.subject | protein conformation | en_US |
dc.subject | structure activity relation | en_US |
dc.subject | synthesis | en_US |
dc.subject | tumor cell line | en_US |
dc.subject | Antineoplastic Agents | en_US |
dc.subject | Cell Line, Tumor | en_US |
dc.subject | Chemistry Techniques, Synthetic | en_US |
dc.subject | Drug Screening Assays, Antitumor | en_US |
dc.subject | Enzyme Inhibitors | en_US |
dc.subject | Humans | en_US |
dc.subject | Molecular Docking Simulation | en_US |
dc.subject | Protein Conformation | en_US |
dc.subject | Structure-Activity Relationship | en_US |
dc.subject | Thiouracil | en_US |
dc.subject | Thymidylate Synthase | en_US |
dc.title | Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., Thun, M.J., Cancer statistics, 2005 (2005) CA Cancer J Clin, 55, pp. 10-30. , PID: 15661684; Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation (2011) Cell, 144, pp. 646-674. , COI: 1:CAS:528:DC%2BC3MXjsFeqtrk%3D, PID: 21376230; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016 (2016) CA Cancer J Clin, 66, pp. 7-30. , PID: 26742998; Eissa, I.H., El-Naggar, A.M., El-Hashash, M.A., Design, synthesis, molecular modeling and biological evaluation of novel 1H-pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents (2016) Bioorg Chem, 67, pp. 43-56. , COI: 1:CAS:528:DC%2BC28XovVejtbk%3D, PID: 27253830; Cancer, , http://www.who.int/cancer/en/, WHOAccess 22 May 2016; Costi, M.P., Tondi, D., Rinaldi, M., Barlocco, D., Pecorari, P., Soragni, F., Venturelli, A., Stroud, R.M., Structure-based studies on species-specific inhibition of thymidylate synthase (2002) Biochim Biophys Acta, 1587, pp. 206-214. , COI: 1:CAS:528:DC%2BD38XkslKjuro%3D, PID: 12084462; Carreras, C.W., Santi, D.V., The catalytic mechanism and structure of thymidylate synthase (1995) Annu Rev Biochem, 64, pp. 721-762. , COI: 1:CAS:528:DyaK2MXmsl2qtrg%3D, PID: 7574499; Backus, H., Wouters, D., Ferreira, C., Van Houten, V., Brakenhoff, R., Pinedo, H., Peters, G., Thymidylate synthase inhibition triggers apoptosis via caspases-8 and-9 in both wild-type and mutant p53 colon cancer cell lines (2003) Eur J Cancer, 39, pp. 1310-1317. , COI: 1:CAS:528:DC%2BD3sXjvFelu74%3D, PID: 12763222; Berman, E., Werbel, L.M., The renewed potential for folate antagonists in contemporary cancer chemotherapy (1991) J Med Chem, 34, pp. 479-485. , COI: 1:CAS:528:DyaK3MXnsVGntA%3D%3D, PID: 1995868; Pinedo, H.M., Peters, G., Fluorouracil: biochemistry and pharmacology (1988) J Clin Oncol, 6, pp. 1653-1664. , COI: 1:CAS:528:DyaL1MXotA%3D%3D, PID: 3049954; Bretner, M., Kulikowski, T., Dzik, J.M., Balinska, M., Rode, W., Shugar, D., 2-thio derivatives of durd and 5-fluoro-durd and their 5�-monophosphates: Synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity (1993) J Med Chem, 36, pp. 3611-3617. , COI: 1:CAS:528:DyaK2cXnslGktg%3D%3D, PID: 8246229; Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Holmgren, E., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer (2004) N Engl J Med, 350, pp. 2335-2342. , COI: 1:CAS:528:DC%2BD2cXks1Gjt74%3D, PID: 15175435; Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Ghiringhelli, F., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity (2010) Cancer Res, 70, pp. 3052-3061. , COI: 1:CAS:528:DC%2BC3cXkslShsLk%3D, PID: 20388795; Macchia, M., Barontini, S., Bertini, S., Di Bussolo, V., Fogli, S., Giovannetti, E., Grossi, E., Danesi, R., Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues (2001) J Med Chem, 44, pp. 3994-4000. , COI: 1:CAS:528:DC%2BD3MXntF2hsrY%3D, PID: 11689086; Sayre, P.H., Finer-Moore, J.S., Fritz, T.A., Biermann, D., Gates, S.B., Mackellar, W.C., Patel, V.F., Stroud, R.M., Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases (2001) J Mol Biol, 313, pp. 813-829. , COI: 1:CAS:528:DC%2BD3MXotVyntLc%3D, PID: 11697906; Tsavaris, N., Kosmas, C., Vadiaka, M., Koufos, C., Raltitrexed (tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-fluorouracil/leucovorin chemotherapy (2002) BMC Cancer, 2, p. 2. , PID: 11860608; Scagliotti, G.V., Parikh, P., Von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Zukin, M., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer (2008) J Clin Oncol, 26, pp. 3543-3551. , COI: 1:CAS:528:DC%2BD1cXpvVWmtLg%3D, PID: 18506025; Jhawer, M., Rosen, L., Dancey, J., Hochster, H., Hamburg, S., Tempero, M., Clendeninn, N., Mani, S., Phase ii trial of nolatrexed dihydrochloride [thymitaqtm, ag 337] in patients with advanced hepatocellular carcinoma (2007) Invest New Drugs, 25, pp. 85-94. , COI: 1:CAS:528:DC%2BD28XhtFegtrfE, PID: 16957834; Appelt, K., Bacquet, R.J., Bartlett, C.A., Booth, C.L., Freer, S.T., Mam, F., Gehring, M.R., Howland, E.F., Design of enzyme inhibitors using iterative protein crystallographic analysis (1991) J Med Chem, 34, pp. 1925-1934. , COI: 1:CAS:528:DyaK3MXksVCltLs%3D, PID: 2066965; Reich, S.H., Mam, F., Nguyen, D., Pino, M.J., Welsh, K.M., Webber, S., Janson, C.A., Matthews, D.A., Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis (1992) J Med Chem, 35, pp. 847-858. , COI: 1:CAS:528:DyaK38Xht1yktbc%3D, PID: 1548676; Varney, M.D., Marzoni, G.P., Palmer, C.L., Deal, J.G., Webber, S., Welsh, K.M., Bacquet, R.J., Morse, C.A., Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase (1992) J Med Chem, 35, pp. 663-676. , COI: 1:CAS:528:DyaK38Xht1ymtLg%3D, PID: 1542093; Webber, S.E., Bleckman, T.M., Attard, J., Deal, J.G., Kathardekar, V., Welsh, K.M., Webber, S., Matthews, D.A., Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones (1993) J Med Chem, 36, pp. 733-746. , COI: 1:CAS:528:DyaK3sXitlequ74%3D, PID: 8459400; Arooj, M., Sakkiah, S., Ping Cao, G., Lee, K.W., An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes (2013) PLoS ONE, 8. , COI: 1:CAS:528:DC%2BC3sXmtlSgsLw%3D, PID: 23577115; Gangjee, A., Devraj, R., Mcguire, J.J., Kisliuk, R.L., 5-arylthio substituted 2-amino-4-oxo-6-methylpyrrolo[2,3-d]pyrimidine antifolates as thymidylate synthase inhibitors and antitumor agents (1995) J Med Chem, 38, pp. 4495-4502. , COI: 1:CAS:528:DyaK2MXosV2qs7Y%3D, PID: 7473577; Fleming, F.F., Yao, L., Ravikumar, P., Funk, L., Shook, B.C., Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore (2010) J Med Chem, 53, pp. 7902-7917. , COI: 1:CAS:528:DC%2BC3cXhtV2kurvP, PID: 20804202; Laurence, C., Brameld, K.A., Graton, J., Le Questel, J.-Y., Renault, E., The p k bhx database: toward a better understanding of hydrogen-bond basicity for medicinal chemists (2009) J Med Chem, 52, pp. 4073-4086. , COI: 1:CAS:528:DC%2BD1MXnsFKns7w%3D, PID: 19537797; Teno, N., Miyake, T., Ehara, T., Irie, O., Sakaki, J., Ohmori, O., Gunji, H., Hitomi, Y., Novel scaffold for cathepsin k inhibitors (2007) Bioorg Med Chem Lett, 17, pp. 6096-6100. , COI: 1:CAS:528:DC%2BD2sXhtFOjt77N, PID: 17911019; Gaillard, H., Garc�a-Muse, T., Aguilera, A., Replication stress and cancer (2015) Nat Rev Cancer, 15, pp. 276-289. , COI: 1:CAS:528:DC%2BC2MXht1Wrur3K, PID: 25907220; Ravichandran, J., Gurumoorthy, P., Karthick, C., Rahiman, A.K., Mononuclear zinc (ii) complexes of 2-((2-(piperazin-1-yl)ethylimino)methyl)-4-substituted phenols: synthesis, structural characterization, DNA binding and cheminuclease activities (2014) J Mol Struct, 1062, pp. 147-157. , COI: 1:CAS:528:DC%2BC2cXjtlWju74%3D; Shankaraiah, N., Jadala, C., Nekkanti, S., Senwar, K.R., Nagesh, N., Shrivastava, S., Naidu, V., Kamal, A., Design and synthesis of c3-tethered 1,2,3-triazolo- ? -carboline derivatives: anticancer activity, DNA-binding ability, viscosity and molecular modeling studies (2016) Bioorg Chem, 64, pp. 42-50. , COI: 1:CAS:528:DC%2BC2MXhvFeqsLrM, PID: 26657602; Li, X.-C., Liu, K.-G., Qin, D.-A., Cheng, C.-C., Chen, B.-X., Hu, M.-L., Influence of bromoethyl group on biological activity of 5-fluorouracil prodrug: insights from x-ray crystallography and molecular docking (2012) J Mol Struct, 1027, pp. 104-110. , COI: 1:CAS:528:DC%2BC38XhsFWhsLfI; Nadzri, N.I., Sabri, N.H., Lee, V.S., Halim, S.N.A., 5-fluorouracil co-crystals and their potential anti-cancer activities calculated by molecular docking studies (2016) J Chem Crystallogr, 46, pp. 144-154. , COI: 1:CAS:528:DC%2BC28XivFKnt7w%3D; Ding, Y., Girardet, J.-L., Smith, K.L., Larson, G., Prigaro, B., Wu, J.Z., Yao, N., Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase (2006) Bioorg chem, 34, pp. 26-38. , COI: 1:CAS:528:DC%2BD28XhtFWjtbs%3D, PID: 16360193; Skehan, P., Storeng, R., Scudiero, D., Monks, A., Mcmahon, J., Vistica, D., Warren, J.T., Boyd, M.R., New colorimetric cytotoxicity assay for anticancer-drug screening (1990) J Natl Cancer Inst, 82, pp. 1107-1112. , COI: 1:CAS:528:DyaK3cXltVylsL8%3D, PID: 2359136; Wahba, A.J., Friedkin, M., The enzymatic synthesis of thymidylate i. Early steps in the purification of thymidylate synthetase of Escherichia coli (1962) J Biol Chem, 237, pp. 3794-3801. , COI: 1:CAS:528:DyaF38XkvVGhsLw%3D, PID: 13998281, PMID:13959775; Jarmu?a, A., Fr?czyk, T., Cieplak, P., Rode, W., Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase (2010) Bioorg Med Chem, 18, pp. 3361-3370. , PID: 20430630; Schmidt, S.D., Mazzella, M.J., Nixon, R.A., Mathews, P.M., A ? measurement by enzyme-linked immunosorbent assay (2012) Amyloid Proteins Methods Protocols, 34, pp. 507-527; Autodock 4.2.6 download page, , http://autodock.scripps.edu/downloads/autodock-registration/autodock-4-2-download-page, AutodockAccess Mar 2016; Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J., Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function (1998) J Comput Chem, 19, pp. 1639-1662. , COI: 1:CAS:528:DyaK1cXntFemur4%3D; Acd/chemsketch for academic and personal use, , http://www.acdlabs.com/resources/freeware/chemsketch/, Acd/LabsAccess Mar 2016; Ju6, , http://www.rcsb.org/pdb/explore/explore.do?structureId=1JU6, PdbAccess Mar 2016; Deepview-swiss-pdbviewer, , http://spdbv.vital-it.ch/disclaim.html, ExpasyAccess Mar 2016; Pymol downloads and documentation, , https://pymol.org/dsc/index.php?ip=, PymolAccess Mar 2016 | |
dcterms.source | Scopus |